| Cat.No. | Name | Information |
|---|---|---|
| M4838 | TAK-242 (Resatorvid) | Resatorvid (TAK-242) is a selective TLR4 signaling inhibitor. Resatorvid inhibited the production of NO, TNF-α and IL-6 with IC50 values of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid down-regulates the expression of MyD88 and TRIF signaling molecules downstream of TLR4. Resatorvid inhibits autophagy and plays a key role in a variety of inflammatory diseases. |
| M11408 | Hydroxychloroquine | Hydroxychloroquine is a synthetic antimalarial agent that also inhibits Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine effectively inhibited SARS-COV-2 infection. |
| M9063 | TLR2-IN-C29 | C29 is a Toll-like receptor 2 (TLR2) inhibitor. C29 blocked HTLR2/1 and HTLR2/6 with IC50 values of 19.7 and 37.6 μM, respectively. |
| M42066 | Polyinosinic acid | Polyinosinic acid is a single stranded homonucleic acid, which is a Toll-like Receptor 3 (TLR3) agonist. |
| M5062 | Polyinosinic acid: polycytidylic acid (poly I:C) | Polyinosinic acid: polycytidylic acid (poly I:C) is a synthetic polyinosinic-polycytidylic acid double-stranded RNA. Polyinosinic-polycytidylic acid (Poly (I:C)) is an agonist of toll-like receptor (TLR)-3. Polyinosinic-polycytidylic acid has protective effects against cerebral ischemia/reperfusion (I/R) injury and can be used as vaccine adjuvant to enhance innate and adaptive immune responses. |
| M42069 | RDR 02308 | RDR 02308 is a TLR4-MyD88 binding inhibitor that inhibits full-length β-lactamase. |
| M42068 | M62812 free base | M62812 (free base) is a toll-like receptor 4 (TLR4) signal transduction inhibitor. |
| M42067 | BMS905 | BMS905 is an orally active TLR7 and TLR8 dual inhibitor (IC50s: 0.7 and 3.2 nM respectively). |
| M42066 | Polyinosinic acid | Polyinosinic acid is a single stranded homonucleic acid, which is a Toll-like Receptor 3 (TLR3) agonist. |
| M42065 | TAT-CIRP | TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. |
| M42064 | Tilsotolimod | Tilsotolimod is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. |
| M42063 | TLR7/8 agonist 8 | TLR7/8 agonist 8 is a potent toll-like receptor 7/8 (TLR7/8) dual agonist, with EC50s of 27 and 12 nM for hTLR7 and hTLR8, respectively. |
| M42062 | Tilsotolimod sodium | Tilsotolimod (sodium) is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. |
| M40904 | ODN TTAGGG | ODN TTAGGG is an inhibitory oligodeoxynucleotide (ODN) as well as a TLR9, AIM2 and cGAS antagonist with immunosuppressive activity, which inhibits the activation of the AIM2 inflammasome by competing with DNA, as well as the activation of cGAS. It can be used in the study of autoimmune diseases such as lupus erythematosus. Sequence: 5'-T-T-T-A-G-G-G-T-T-T-T-A-G-G-G-T-T-T-A-G-G-G-T-T-T-A-G-G-G-T-T-T-A-G-G-G-3'. |
| M31226 | Chitohexaose hexahydrochloride | Chitohexaose hexahydrochloride is a chitosan oligosaccharide with anti-inflammatory effect. Chitohexaose hexahydrochloride binds to the active sites of TLR4 and inhibits LPS induced inflammation. |
| M30937 | ODN 1018 | ODN 1018 (1018 ISS), an oligodeoxynucleotide, is a TLR-9 agonist. ODN 1018 is also a synthetic immunostimulatory sequence that can be used as vaccine adjuvant. Sequence: 5′-TGACTGTGAACGTTCGAGATGA-3′. |
| M30420 | 3M-011 | 3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action. |
| M29946 | L48H37 | L48H37 is an analog of Curcumin with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment. |
| M29890 | MMG-11 | MMG-11 is a potent and selective human TLR2 antagonist with low cytotoxicity. MMG-11 inhibits both TLR2/1 and TLR2/6 signaling with IC50s of 1.7 µM for Pam3CSK4-induced hTLR2/1 and 5.7 µM for Pam2CSK4-induced hTLR2/6 responses. |
| M29713 | CL075 | CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively. |
| M29589 | Polvitolimod | Polvitolimod is a TLR7 agonist for research of cancer and infectious disease. |
| M29469 | SM-360320 | SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response. SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity. |
| M28075 | TLR7/8 agonist 1 | TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline. |
| M28000 | GSK1795091 | GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. |
| M27994 | TLR7 agonist 3 | TLR7 agonist 3 (Compound 2) is a potent agonist of toll-like receptor 7 (TLR7). TLR7 has an important role in immune activation processes and represents an emerging agent discovery target for the development of immunomodulators. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
